Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
Amastatin hydrochloride (HB3757)
Description:Competitive aminopeptidase (AP) inhibitor
Purity:>98%
-
Ambuic acid (HB3759)
Description:Antibiotic with antibacterial and antifungal activities
Purity:>95%
-
AMD 3100 octahydrochloride (HB2739)
Description:Potent, selective CXCR4 antagonist. Mobilizes hematopoietic stem cells.
- Description:
Ribosome-borne protein folding activity (RPFA) inhibitor
Purity:>99%
-
6-Aminophenanthridine (HB3730)
Description:Ribosome-borne protein folding activity (RPFA) inhibitor
Purity:>97%
-
-
-
β-Amyloid Peptide (1-42) (human) (HB9805)
Description:β-Amyloid (1-42) protein fragment. Implicated in Alzheimer's disease.
-
-
